研究業績

論文業績　2009～

2010

  1. 1.Anraku M, Michihara A, Yasufuku T, Akasaki K, Tsuchiya D, Nishio H, Maruyama T, Otagiri M, Maezaki Y, Kondo Y, Tomida H. The antioxidative and antilipidemic effects of different molecular weight chitosans in metabolic syndrome model rats. Biol Pharm Bull. 2010;33(12):1994-8.
  2. 2.Taguchi K, Iwao Y, Watanabe H, Kadowaki D, Sakai H, Kobayashi K, Horinouchi H, Maruyama T, Otagiri M. Repeated injection of high doses of hemoglobin-encapsulated liposomes (hemoglobin vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model. Drug Metab Dispos. 2011 Mar;39(3):484-9.
  3. 3.Taguchi K, Urata Y, Anraku M, Watanabe H, Kawai K, Komatsu T, Tsuchida E, Maruyama T, Otagiri M. Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander. Drug Metab Dispos. 2010 Dec;38(12):2124-9.
  4. 4.Taguchi K, Miyasato M, Watanabe H, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M. Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity. J Pharm Sci. 2011 Feb;100(2):775-83.
  5. 5.Taguchi K, Miyasato M, Ujihira H, Watanabe H, Kadowaki D, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M. Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment. Toxicol Appl Pharmacol. 2010 Nov 1;248(3):234-41.
  6. 6.Ikuta S, Chuang VT, Ishima Y, Nakajou K, Furukawa M, Watanabe H, Maruyama T, Otagiri M. Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications. J Control Release. 2010 Oct 1;147(1):17-23.
  7. 7.Nishi K, Fukunaga N, Ono T, Akuta T, Yumita N, Watanabe H, Kadowaki D, Suenaga A, Maruyama T, Otagiri M. Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties. Drug Metab Pharmacokinet. 2010;25(2):200-7.
  8. 8.Ishima Y, Hiroyama S, Kragh-Hansen U, Maruyama T, Sawa T, Akaike T, Kai T, Otagiri M. One-step preparation of S-nitrosated human serum albumin with high biological activities. Nitric Oxide. 2010 Sep 15;23(2):121-7.
  9. 9.Miyamoto Y, Iwao Y, Tasaki Y, Sato K, Ishima Y, Watanabe H, Kadowaki D, Maruyama T, Otagiri M. The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions. FEBS Lett. 2010 Jul 2;584(13):2816-20.
  10. 10.Hirata K, Maruyama T, Watanabe H, Maeda H, Nakajou K, Iwao Y, Ishima Y, Katsumi H, Hashida M, Otagiri M. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J Control Release. 2010 Jul 1;145(1):9-16.
  11. 11.Matsumoto K, Nishi K, Kikuchi M, Watanabe H, Nakajou K, Komori H, Kadowaki D, Suenaga A, Maruyama T, Otagiri M. Receptor-mediated uptake of human alpha1-acid glycoprotein into liver parenchymal cells in mice. Drug Metab Pharmacokinet. 2010;25(1):101-7.
  12. 12.Katayama N, Nakajou K, Ishima Y, Ikuta S, Yokoe J, Yoshida F, Suenaga A, Maruyama T, Kai T, Otagiri M. Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. Nitric Oxide. 2010 May 15;22(4):259-65.
  13. 13.Mera K, Takeo K, Izumi M, Maruyama T, Nagai R, Otagiri M. Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin. J Pharm Sci. 2010 Mar;99(3):1614-25.